Goch, Germany (23rd January 2020) - The transaction of Fonterra’s 50% share of DFE Pharma to CVC Strategic Opportunities II has been finalized. In September last year, Fonterra announced the sale of its 50% share of DFE Pharma, a joint venture with FrieslandCampina. Completion of the sale was subject to regulatory approvals from competition authorities, and these have now all been received.
DFE Pharma CEO, Bas van Driel, says “I am proud of the success achieved by DFE Pharma to date. The joint venture of 2 global leading dairy cooperatives has created this leading global excipient company, and has laid the foundation on which we will continue to grow our business both organically and by acquisitions.”
“We are delighted to have the support of CVC, a leading global investor, to expand DFE Pharma and take the company to the next level.", Mr van Driel says.
The change in ownership of DFE Pharma will not affect our supply of excipients. Fonterra will stay committed to the business through a long-term supply agreement.